ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 03 May 2017
Last Updated on 01 Jul 2022
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Denosumab 60 mg/mL prefilled syringe for treating patients with osteoporosis (T-score ≤ -2.5) at high risk of fracture.
Patients must also receive adequate calcium and vitamin D supplementation whilst undergoing treatment.

Subsidy status
Denosumab 60 mg/mL prefilled syringe is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 July 2022.

MAF assistance does not apply to denosumab 60 mg/mL prefilled syringe when used for treating glucocorticoid-associated bone loss.

Denosumab for treating osteoporosis and glucocorticoid-associated bone loss (Updated 1 July 22) PES Denosumab for treating osteoporosis (Published 1 July 2022)